Phase 2 Trial of Neoadjuvant KRAS G12C directed therapy with Adagrasib (MRTX849) with or without Nivolumab in Resectable Non-Small Cell Lung Cancer (Neo-KAN)
Study of Adagrasib Alone or in Combination with Nivolumab Non-Small Cell Lung Cancer (NSCLC)
Sponsor: Johns Hopkins
Enrolling: Male and Female Patients
IRB Number: AAAU8381
U.S. Govt. ID: NCT05472623
Contact: Research Nurse Navigator: 212-342-5162 /
Additional Study Information: The purpose of this study is to assess the benefits and risks of the study drug, adagrasib, when given either by itself or with another drug, nivolumab, to participants with non-small cell lung cancer and a specific cancer mutation, called KRAS G12C, and whether the study drug or the combination may treat or shrink tumors when given before cancer surgery. The goal of studying this approach is to improve treatment of this cancer and decrease the chance that cancer relapses after surgery. The use of adagrasib in this research study is investigational. The word investigational means that adagrasib is not approved for marketing, or to treat lung cancer, by the Food and Drug Administration (FDA). Nivolumab is approved by the Food and Drug Administration (FDA) for the treatment of lung cancer. However, combining nivolumab with adagrasib is not FDA-approved and is investigational in this study. There are two study groups: Group A and Group B. Group A will receive adagrasib alone. Group B will receive adagrasib and nivolumab.
Benjamin Herzberg, MD
Do You Qualify?
Are you at least 18 years old? Yes No
Have you been diagnosed with Non-Small Cell Lung Cancer (NSCLC)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Research Nurse Navigator